Scholarlink

Background <p>Colorectal cancer (CRC) is a global health burden because of its high mortalities. It is crucial to discover new biomarkers that can help predict the outcome of patients as well as identify new therapeutic targets to improve treatment options for CRC patients. EGLN1, a protein belonging to the family of prolyl hydroxylase domain-containing proteins, has been associated with the progression of various cancer types. However, its involvement in CRC remains uncertain.</p> Methods <p>We conducted an analysis of EGLN1 expression levels in colorectal cancer (CRC) tissues using publicly available datasets. EGLN1 expression was also evaluated in relation to patient survival. To explore the potential biological functions and signaling pathways associated with EGLN, we performed gene set enrichment analysis (GSEA). We also investigated the immune landscape of EGLN1 in CRC by examining its association with immune infiltration and immune-related markers.</p> Results <p>We consistently observed a significant decrease in EGLN1 level in CRC tumor tissues when compared to normal tissues, indicating its potential role as a tumor suppressor gene specific to CRC. The diagnostic potential of EGLN1 was substantiated by its effective discrimination between normal and tumor tissues in patients with CRC. Functional enrichment analysis further uncovered EGLN1’s involvement in the regulation of crucial biological processes, cellular components, and molecular functions relevant to CRC development and progression. The correlation analysis revealed the potential immunomodulatory role of EGLN1, affecting immune checkpoint molecules, antigen presentation, and immune cell trafficking within the tumor microenvironment. Additionally, high level of EGLN1 exhibited a significant association with improved recurrence-free survival (RFS) and emerged as an independent prognostic factor. Knockdown experiments demonstrated EGLN1’s role in suppressing cell proliferation and migration in CRC.</p> Conclusion <p>In summary, our findings position EGLN1 as a promising multi-faceted biomarker in CRC, with implications for prognosis, immune microenvironment modulation, and potential therapeutic targeting.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the prognostic value and immune landscape of EGLN1 in colorectal cancer: insights from bioinformatics analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月2日

查看全文
  • Xiawu Chen,
  • Chengqing Huang,
  • Yingping Liao,
  • Xiaoxun Chen

摘要

Background

Colorectal cancer (CRC) is a global health burden because of its high mortalities. It is crucial to discover new biomarkers that can help predict the outcome of patients as well as identify new therapeutic targets to improve treatment options for CRC patients. EGLN1, a protein belonging to the family of prolyl hydroxylase domain-containing proteins, has been associated with the progression of various cancer types. However, its involvement in CRC remains uncertain.

Methods

We conducted an analysis of EGLN1 expression levels in colorectal cancer (CRC) tissues using publicly available datasets. EGLN1 expression was also evaluated in relation to patient survival. To explore the potential biological functions and signaling pathways associated with EGLN, we performed gene set enrichment analysis (GSEA). We also investigated the immune landscape of EGLN1 in CRC by examining its association with immune infiltration and immune-related markers.

Results

We consistently observed a significant decrease in EGLN1 level in CRC tumor tissues when compared to normal tissues, indicating its potential role as a tumor suppressor gene specific to CRC. The diagnostic potential of EGLN1 was substantiated by its effective discrimination between normal and tumor tissues in patients with CRC. Functional enrichment analysis further uncovered EGLN1’s involvement in the regulation of crucial biological processes, cellular components, and molecular functions relevant to CRC development and progression. The correlation analysis revealed the potential immunomodulatory role of EGLN1, affecting immune checkpoint molecules, antigen presentation, and immune cell trafficking within the tumor microenvironment. Additionally, high level of EGLN1 exhibited a significant association with improved recurrence-free survival (RFS) and emerged as an independent prognostic factor. Knockdown experiments demonstrated EGLN1’s role in suppressing cell proliferation and migration in CRC.

Conclusion

In summary, our findings position EGLN1 as a promising multi-faceted biomarker in CRC, with implications for prognosis, immune microenvironment modulation, and potential therapeutic targeting.